CGC vs. PHVS, CRMD, AKBA, OCS, LENZ, ZYME, PRAX, CMRX, CDMO, and NUVB
Should you be buying Canopy Growth stock or one of its competitors? The main competitors of Canopy Growth include Pharvaris (PHVS), CorMedix (CRMD), Akebia Therapeutics (AKBA), Oculis (OCS), LENZ Therapeutics (LENZ), Zymeworks (ZYME), Praxis Precision Medicines (PRAX), Chimerix (CMRX), Avid Bioservices (CDMO), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry.
Canopy Growth vs.
Pharvaris (NASDAQ:PHVS) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, community ranking, profitability, analyst recommendations, earnings and dividends.
Pharvaris currently has a consensus target price of $37.25, indicating a potential upside of 105.57%. Canopy Growth has a consensus target price of $2.00, indicating a potential upside of 33.33%. Given Pharvaris' stronger consensus rating and higher probable upside, research analysts clearly believe Pharvaris is more favorable than Canopy Growth.
Pharvaris has higher earnings, but lower revenue than Canopy Growth. Pharvaris is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.
Pharvaris has a beta of -2.86, meaning that its share price is 386% less volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500.
Pharvaris received 19 more outperform votes than Canopy Growth when rated by MarketBeat users. Likewise, 67.24% of users gave Pharvaris an outperform vote while only 19.05% of users gave Canopy Growth an outperform vote.
3.3% of Canopy Growth shares are held by institutional investors. 11.8% of Pharvaris shares are held by company insiders. Comparatively, 1.3% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Pharvaris has a net margin of 0.00% compared to Canopy Growth's net margin of -156.98%. Pharvaris' return on equity of -38.52% beat Canopy Growth's return on equity.
In the previous week, Canopy Growth had 4 more articles in the media than Pharvaris. MarketBeat recorded 18 mentions for Canopy Growth and 14 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.63 beat Canopy Growth's score of 0.30 indicating that Pharvaris is being referred to more favorably in the media.
Summary
Pharvaris beats Canopy Growth on 11 of the 17 factors compared between the two stocks.
Get Canopy Growth News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Canopy Growth Competitors List
Related Companies and Tools
This page (NASDAQ:CGC) was last updated on 6/10/2025 by MarketBeat.com Staff
Buy CGC Stock Free CGC Stock Alerts